NO922530L - Cykliske imid-derivater - Google Patents

Cykliske imid-derivater

Info

Publication number
NO922530L
NO922530L NO92922530A NO922530A NO922530L NO 922530 L NO922530 L NO 922530L NO 92922530 A NO92922530 A NO 92922530A NO 922530 A NO922530 A NO 922530A NO 922530 L NO922530 L NO 922530L
Authority
NO
Norway
Prior art keywords
cyclic imid
derivatives
imid derivatives
cyclic
imid
Prior art date
Application number
NO92922530A
Other languages
English (en)
Norwegian (no)
Other versions
NO922530D0 (no
Inventor
Peter Leslie Myers
Andrew Brian Mcelroy
Michael Gregson
Peter Jonathan Brown
Howard Geoffrey Davies
David Harold Drewry
Michael Andrew Foley
Original Assignee
Glaxo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919113844A external-priority patent/GB9113844D0/en
Priority claimed from GB919113930A external-priority patent/GB9113930D0/en
Priority claimed from GB929209402A external-priority patent/GB9209402D0/en
Priority claimed from GB929210343A external-priority patent/GB9210343D0/en
Application filed by Glaxo Inc filed Critical Glaxo Inc
Publication of NO922530D0 publication Critical patent/NO922530D0/no
Publication of NO922530L publication Critical patent/NO922530L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO92922530A 1991-06-27 1992-06-26 Cykliske imid-derivater NO922530L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919113844A GB9113844D0 (en) 1991-06-27 1991-06-27 Chemical compounds
GB919113930A GB9113930D0 (en) 1991-06-27 1991-06-27 Chemical compounds
GB929209402A GB9209402D0 (en) 1992-04-30 1992-04-30 Chemical compounds
GB929210343A GB9210343D0 (en) 1992-05-14 1992-05-14 Chemical compounds

Publications (2)

Publication Number Publication Date
NO922530D0 NO922530D0 (no) 1992-06-26
NO922530L true NO922530L (no) 1992-12-28

Family

ID=27450705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92922530A NO922530L (no) 1991-06-27 1992-06-26 Cykliske imid-derivater

Country Status (10)

Country Link
US (1) US5252560A (fi)
EP (1) EP0520573A1 (fi)
JP (1) JPH0625284A (fi)
KR (1) KR930000481A (fi)
AU (1) AU1864092A (fi)
CA (1) CA2072551A1 (fi)
FI (1) FI922964A (fi)
IE (1) IE922083A1 (fi)
MX (1) MX9203643A (fi)
NO (1) NO922530L (fi)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530161A (en) * 1991-07-08 1996-06-25 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
AUPM627594A0 (en) * 1994-06-16 1994-07-07 Willis, Gregory Lynn Dr Animal bedding material
WO1996033733A1 (fr) * 1995-04-25 1996-10-31 Fuji Yakuhin Kogyo Kabushiki Kaisha Nouveau remede pour affections cutanees
GB9613547D0 (en) * 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
DE60032524T2 (de) * 1999-08-10 2007-07-05 Glaxo Group Ltd., Greenford EP4 Rezeptor Ligand und Verwendung gegen neuropathischen Schmerzen, Colon Krebs, HIV und Migräne
WO2001087849A2 (en) 2000-05-12 2001-11-22 Genzyme Corporation Modulators of tnf- alpha signaling
KR20040094677A (ko) * 2002-01-29 2004-11-10 와이어쓰 코넥신 헤미채널 조절을 위한 조성물 및 방법
US20040157804A1 (en) * 2002-10-16 2004-08-12 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
JP2007532665A (ja) * 2004-04-14 2007-11-15 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖインテグラーゼ阻害剤化合物のホスホネート類似物
EP3102576B8 (en) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
CN104130144A (zh) * 2014-07-30 2014-11-05 新疆农垦科学院 酞酸酯类塑化剂通用半抗原、抗原的合成方法及应用
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
AU2018307919B2 (en) 2017-07-24 2022-12-01 Vitae Pharmaceuticals, Llc Inhibitors of RORϒ
KR20230158005A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2025996A1 (de) * 1970-05-27 1971-12-09 Chemie Grünenthal GmbH, 5190 Stolberg Abkömmlinge von Mercaptocarbonsäuren
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
GB8726714D0 (en) * 1987-11-14 1987-12-16 Beecham Group Plc Compounds
EP0369391A3 (en) * 1988-11-15 1991-09-25 Boehringer Ingelheim Pharmaceuticals Inc. N-substituted amides
EP0401963A1 (en) * 1989-04-13 1990-12-12 Beecham Group p.l.c. Phosphonopeptides with collagenase inhibiting activity
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
WO1991005555A2 (en) * 1989-10-13 1991-05-02 The Salk Institute Biotechnology/Industrial Associates, Inc. N-acyl peptide metalloendopeptidase inhibitors and methods of using same
WO1991005763A1 (en) * 1989-10-13 1991-05-02 The Salk Institute Biotechnology/Industrial Associates, Inc. Dipeptide-analog-based metalloendopeptidase inhibitors and methods of using same
WO1991008222A1 (fr) * 1989-11-24 1991-06-13 Banyu Pharmaceutical Co., Ltd. Substance physiologiquement active be-16627
GB9008065D0 (en) * 1990-04-10 1990-06-06 Beecham Group Plc Novel compounds
GB9008078D0 (en) * 1990-04-10 1990-06-06 Beecham Group Plc Novel compounds
DE69132708T2 (de) * 1990-09-24 2002-06-20 Philadelphia Health And Education Corp., Philadelphia Therapeutische Vervendung von Peptiden mit Thrombospondin - ähnlicher Aktivität
CA2073513A1 (en) * 1990-12-03 1992-06-04 John Robert Porter Peptidyl derivatives

Also Published As

Publication number Publication date
MX9203643A (es) 1995-01-31
EP0520573A1 (en) 1992-12-30
CA2072551A1 (en) 1992-12-28
US5252560A (en) 1993-10-12
IE922083A1 (en) 1992-12-30
NO922530D0 (no) 1992-06-26
AU1864092A (en) 1993-01-07
KR930000481A (ko) 1993-01-15
JPH0625284A (ja) 1994-02-01
FI922964A0 (fi) 1992-06-26
FI922964A (fi) 1992-12-28

Similar Documents

Publication Publication Date Title
NO922530L (no) Cykliske imid-derivater
DE69208877D1 (de) Chinuclidinderivate
NO922182L (no) Krystallinske oksatiolan-derivater
DE59208415D1 (de) 3-Hydroxy-4-aryl-5-oxo-pyrazolin Derivate
NO923618D0 (no) Benzanilid-derivater
NO923617L (no) Benzanilid-derivater
DE69119329D1 (de) Actinonin-Derivate
FI925763A0 (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
DE69125099D1 (de) Indolderivate
DK0449079T3 (da) Hydantoinderivater
DE69212058D1 (de) Indol-Derivate
ATE171449T1 (de) Oxadolderivate
TR26336A (tr) SüBSTITüE EDILMIS PIRAZOLIN TüREVLERI
NO923581D0 (no) Sykliske substituerte imidazolylpropensyrederivater
DE69216260D1 (de) Piperidinderivate
DE69221652D1 (de) Substituiertes cyclisches Sulfamidderivat
DE69222599D1 (de) Cephalosporin-Derivate
NO920420L (no) 3-quinuklidin-derivater
FI925469A (fi) Tiazolylsubstituerade kinolylymetoxifenylaettiksyraderivat
MX9206710A (es) Derivados de piridinol
NO924543L (no) Maktocykliske laktamderivater
DE69211197D1 (de) 1-Hydroxyvitamin D-Derivate
KR930702353A (ko) 2- 카르바페넴 유도체
BG96179A (bg) Амидинови производни
NO923538D0 (no) Cykliske nitroner